Orasis Prepares To Battle AbbVie In Presbyopia

Qlosi Clears US FDA

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

The privately held firm got FDA approval for Qlosi, which like AbbVie’s Vuity is a low-dose formulation of pilocarpine for age-related near vision loss. Launch is planned for early 2024.

eye%20drops.jpg
Orasis's Qlosi will compete directly against AbbVie's Vuity

AbbVie Inc. will have direct competition for its presbyopia product Vuity, since privately held Orasis Pharmaceuticals Ltd. got US Food and Drug Administration approval for the same indication on 18 October for Qlosi, which like the AbbVie product is a low-dose formulation of the ophthalmic drug pilocarpine. The Florida company said it will launch Qlosi and disclose the product’s pricing in early 2024, but indicated that it would price its product in the same range as Vuity.

Key Takeaways

  • Orasis obtained US FDA approval of Qlosi, a low-dose pilocarpine eyedrop to treat presbyopia, age-related loss of near vision.

Both products will compete primarily with reading glasses and Orasis president Paul Smith told Scrip that his company sees presbyopia...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

Scrip-NewProducts (Premium-2): Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 
• By Nabil

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 
• By Dexter Jie Yan

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 
• By Alexandra Shimmings

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains